

## p38 MAPK (Phospho-Tyr182) Antibody Blocking Peptide

Catalog Number: 51253-1, 51253-2

**Amount:** 50μg/50μl, 100μg/100μl

Form of Peptide: Peptide in 10 mM phosphate buffered saline (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150mM NaCl,

0.1 mM EDTA, 1 mg/ml BSA, 5% DMF and 5% glycerol.

Peptide Information: The synthesized phosphopeptide was derived from human p38 MAPK around the

phosphorylation site of 182 (T-G-Y<sup>P</sup>-V-A)

Storage: Store at -20°C.

Quality Control: The quality of the peptide was evaluated by reversed-phase HPLC and mass spectrometry.

**Specificity:** The peptide specifically blocks the signal p38 MAPK (phospho-Tyr182) antibody (#11253)

completely in Western blotting and IHC.

Applications: For Western blotting:add 10 µl of antibody and 10 µl of blocking peptide to 10 ml of antibody


dilution buffer, and incubate at 4℃ over night or at room temperature for 2 hours before

allowing to react with the blot.


References: Ming Zheng, et al.(2005) The FASEB Journal. 19: 109-111

Bernt van den et al.(2001) Blink Immunology, 166: 582-587

Arshad Rahman, et al. (2004) Am J Physiol Lung Cell Mol Physiol 287: L1017-L1024 Osamu Yoshino, et al. (2003) Endocrinology & Metabolism Vol. 88: 2236-2241



Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using P38 MAPK (phospho- Tyr182) antibody (#11253).



Western blot analysis of extracts from NIH-3T3 (Line 1, 4, 7 and 10) and cos7 (Line 2, 5, 8 and 11 and K562 (Line 3, 6, 9 and 12) cells, untreated or treated with UV (20min), using P38 MAPK (Ab-182) antibody (#21245, Lane 1, 2, 3, 4, 5 and 6) and P38 MAPK (phospho-Tyr182) antibody (#11253, Lane 7, 8, 9, 10, 11 and 12).